Exact Sciences (EXAS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Exact Sciences Revenue Highlights

Latest Revenue (Y)

$2.50B

Latest Revenue (Q)

$708.65M

Main Segment (Y)

Service

Main Geography (Y)

UNITED STATES

Exact Sciences Revenue by Period

Exact Sciences Revenue by Year

Date	Revenue	Change
2023-12-31	$2.50B	19.93%
2022-12-31	$2.08B	17.95%
2021-12-31	$1.77B	18.49%
2020-12-31	$1.49B	70.19%
2019-12-31	$876.29M	92.82%
2018-12-31	$454.46M	70.86%
2017-12-31	$265.99M	167.66%
2016-12-31	$99.38M	151.99%
2015-12-31	$39.44M	2093.38%
2014-12-31	$1.80M	-56.61%
2013-12-31	$4.14M	-
2012-12-31	$4.14M	-0.46%
2011-12-31	$4.16M	-22.10%
2010-12-31	$5.34M	12.32%
2009-12-31	$4.76M	-648.79%
2008-12-31	$-867.00K	-129.54%
2007-12-31	$2.94M	-38.21%
2006-12-31	$4.75M	11.76%
2005-12-31	$4.25M	-13.88%
2004-12-31	$4.93M	70.11%
2003-12-31	$2.90M	223.41%
2002-12-31	$897.00K	1663.32%
2001-12-31	$50.87K	5086900.00%
2000-12-31	$1.00	100.00%
1999-12-31	-	100.00%
1998-12-31	-	-

Exact Sciences generated $2.50B in revenue during NA 2023, up 19.93% compared to the previous quarter, and up 550.05% compared to the same period a year ago.

Exact Sciences Revenue by Quarter

Date	Revenue	Change
2024-09-30	$708.65M	1.34%
2024-06-30	$699.26M	9.68%
2024-03-31	$637.52M	-1.45%
2023-12-31	$646.88M	2.95%
2023-09-30	$628.34M	1.00%
2023-06-30	$622.09M	3.26%
2023-03-31	$602.45M	8.94%
2022-12-31	$553.00M	5.72%
2022-09-30	$523.07M	0.27%
2022-06-30	$521.64M	7.21%
2022-03-31	$486.57M	2.69%
2021-12-31	$473.81M	3.82%
2021-09-30	$456.38M	4.96%
2021-06-30	$434.82M	8.14%
2021-03-31	$402.08M	-13.78%
2020-12-31	$466.34M	14.20%
2020-09-30	$408.36M	51.88%
2020-06-30	$268.87M	-22.70%
2020-03-31	$347.82M	17.68%
2019-12-31	$295.57M	35.09%
2019-09-30	$218.81M	9.47%
2019-06-30	$199.87M	23.34%
2019-03-31	$162.04M	13.33%
2018-12-31	$142.98M	20.87%
2018-09-30	$118.29M	14.96%
2018-06-30	$102.89M	13.95%
2018-03-31	$90.30M	3.31%
2017-12-31	$87.41M	20.44%
2017-09-30	$72.57M	25.90%
2017-06-30	$57.65M	19.19%
2017-03-31	$48.36M	37.24%
2016-12-31	$35.24M	25.35%
2016-09-30	$28.11M	32.71%
2016-06-30	$21.18M	42.80%
2016-03-31	$14.84M	17.44%
2015-09-30	$12.63M	55.59%
2015-06-30	$8.12M	90.32%
2015-03-31	$4.27M	183.64%
2014-12-31	$1.50M	100.00%
2014-09-30	-	100.00%
2014-06-30	-	-100.00%
2014-03-31	$294.00K	-71.62%
2013-12-31	$1.04M	-
2013-09-30	$1.04M	-
2013-06-30	$1.04M	-
2013-03-31	$1.04M	-
2012-12-31	$1.04M	-
2012-09-30	$1.04M	-
2012-06-30	$1.04M	-
2012-03-31	$1.04M	-0.58%
2011-12-31	$1.04M	0.29%
2011-09-30	$1.04M	-0.29%
2011-06-30	$1.04M	0.19%
2011-03-31	$1.04M	-24.36%
2010-12-31	$1.38M	1.40%
2010-09-30	$1.36M	3.20%
2010-06-30	$1.31M	1.15%
2010-03-31	$1.30M	4.42%
2009-12-31	$1.24M	-0.96%
2009-09-30	$1.26M	-0.16%
2009-06-30	$1.26M	25.80%
2009-03-31	$1.00M	-152.74%
2008-12-31	$-1.90M	-662.61%
2008-09-30	$337.00K	100.00%
2008-06-30	-	-100.00%
2008-03-31	$51.00K	-90.50%
2007-12-31	$537.00K	-

Exact Sciences generated $708.65M in revenue during Q3 2024, up 1.34% compared to the previous quarter, and up 113.91% compared to the same period a year ago.

Exact Sciences Revenue Breakdown

Exact Sciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Product and Service, Other	$136.01M	$53.72M	$39.92M	$37.78M	-
International Sales	$117.74M	$109.91M	$77.48M	$11.44M	-
COVID-19 Testing	$58.09M	$143.10M	$235.83M	-	-
Service	$743.24M	$569.94M	$409.67M	$368.01M	$184.54M
Product	$545.46M	$438.65M	$365.47M	$404.33M	$254.43M
Product And Service Other	-	-	-	-	$15.49M

Exact Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 22: Service (46.44%), Product (34.08%), Product and Service, Other (8.50%), International Sales (7.36%), and COVID-19 Testing (3.63%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19
COVID-19 Testing	-	-	-	$5.96M	-	$2.13M	$3.82M	$6.04M	$10.87M	$13.75M	$27.43M	$47.10M	$30.59M	$33.07M	$32.34M	$99.09M	$102.16M	$34.58M	-	-
Product and Service, Other	-	-	-	-	-	$41.02M	$38.43M	$35.99M	$31.47M	$37.46M	$31.09M	$17.38M	$13.04M	$12.40M	$10.89M	$11.56M	$9.77M	$6.67M	$11.92M	-
Product	-	-	-	-	-	$176.02M	$171.73M	$156.09M	$140.37M	$135.25M	$113.75M	$109.61M	$116.09M	$111.39M	$101.56M	$108.88M	$98.85M	$59.58M	$98.16M	$108.62M
Service	-	-	-	-	-	$245.75M	$233.03M	$211.45M	$188.92M	$181.19M	$161.68M	$150.68M	$151.25M	$140.15M	$127.87M	$129.22M	$106.00M	$65.08M	$109.37M	$99.35M
International Sales	-	-	-	-	-	$35.59M	$37.27M	$28.20M	$31.53M	$28.34M	$29.44M	$29.78M	$27.23M	$26.85M	$26.06M	$21.26M	$16.24M	$19.02M	$20.94M	-
Product And Service Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$10.84M

Exact Sciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$1.97B	$1.66B	$1.41B	$864.85M
Non-US	$117.74M	$109.91M	$77.48M	$11.44M

Exact Sciences's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (94.35%), and Non-US (5.65%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Non-US	$49.43M	$46.72M	$44.53M	$153.28M	$38.60M	$35.59M	$37.27M	$31.53M	$28.34M	$29.44M	$27.23M	$26.85M	$26.06M	$21.26M	$16.24M	$19.02M	$20.94M
UNITED STATES	$659.22M	$652.54M	$592.99M	$2.35B	$589.74M	$586.51M	$565.18M	$491.54M	$493.30M	$457.13M	$429.15M	$407.97M	$376.02M	$445.08M	$392.12M	$249.85M	$326.88M

Exact Sciences's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (93.02%), and Non-US (6.98%).

Exact Sciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
TMO	Thermo Fisher Scientific	$42.86B	$10.60B
DHR	Danaher	$14.03B	$3.40B
A	Agilent	$6.83B	$1.58B
ILMN	Illumina	$4.50B	$1.08B
CRL	Charles River Laboratories	$4.13B	$1.03B
EXAS	Exact Sciences	$2.50B	$708.65M
NTRA	Natera	$1.08B	$439.76M
MYGN	Myriad Genetics	$678.40M	$191.90M
GH	Guardant Health	$563.95M	$177.24M
CDNA	CareDx	$280.32M	$82.88M
TWST	Twist Bioscience	$245.11M	$81.46M
CSTL	Castle Biosciences	$219.79M	$85.78M

EXAS Revenue FAQ

What is Exact Sciences’s yearly revenue?

Exact Sciences's yearly revenue for 2023 was $2.5B, representing an increase of 19.93% compared to 2022. The company's yearly revenue for 2022 was $2.08B, representing an increase of 17.95% compared to 2021. EXAS's yearly revenue for 2021 was $1.77B, representing an increase of 18.49% compared to 2020.

What is Exact Sciences’s quarterly revenue?

Exact Sciences's quarterly revenue for Q3 2024 was $708.66M, a 1.34% increase from the previous quarter (Q2 2024), and a 12.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $699.26M, a 9.68% increase from the previous quarter (Q1 2024), and a 12.41% increase year-over-year (Q2 2023). EXAS's quarterly revenue for Q1 2024 was $637.52M, a -1.45% decrease from the previous quarter (Q4 2023), and a 5.82% increase year-over-year (Q1 2023).

What is Exact Sciences’s revenue growth rate?

Exact Sciences's revenue growth rate for the last 3 years (2021-2023) was 41.46%, and for the last 5 years (2019-2023) was 185.27%.

What are Exact Sciences’s revenue streams?

Exact Sciences's revenue streams in c 22 are Product and Service, Other, International Sales, COVID-19 Testing, Service, and Product. Product and Service, Other generated $136.01M in revenue, accounting 8.50% of the company's total revenue, up 153.19% year-over-year. International Sales generated $117.74M in revenue, accounting 7.36% of the company's total revenue, up 7.12% year-over-year. COVID-19 Testing generated $58.09M in revenue, accounting 3.63% of the company's total revenue, down -59.41% year-over-year. Service generated $743.24M in revenue, accounting 46.44% of the company's total revenue, up 30.41% year-over-year. Product generated $545.46M in revenue, accounting 34.08% of the company's total revenue, up 24.35% year-over-year.

What is Exact Sciences’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Exact Sciences was Service. This segment made a revenue of $743.24M, representing 46.44% of the company's total revenue.